Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc., which is a subsidiary) on July 21, 2016. The report details corporate governance actions regarding employee compensation and executive equity grants approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structure of future compensation plans rather than historical financial performance.
Material Changes and Compensation Structure
- 2017 Fiscal Year Bonus Plan: The Board approved performance criteria for cash bonuses for employees of Landec, Apio, Inc., and Lifecore Biomedical, Inc.
- Target Amounts: Executive officers are eligible for 40% to 100% of base salary; other employees are eligible for 6% to 40% of base salary.
- Performance Metrics:
- 20% of the target is based on achieving a specific "all or nothing" strategic goal.
- 80% of the target is based on achieving 100% of target revenue and operating income. Payments are calculated on a sliding scale, with no bonus payable if revenue or operating income falls below 80% of the target.
- Eligibility: Participants must be employed at the end of the 2017 fiscal year to receive any bonus.
Executive Equity Grant
On July 21, 2016, the Board approved an equity grant for Molly Hemmeter, Chief Executive Officer:
- Stock Options: 150,000 shares, vesting monthly over three years.
- Restricted Stock Units (RSUs): 50,000 units, vesting on the third anniversary of the grant.
Outlook and Risks
The filing does not contain forward-looking guidance, risk factors, or management commentary regarding market conditions. The primary contingency noted is that bonus payments are contingent upon the company meeting specific revenue and operating income thresholds and the employee remaining with the company through the end of the fiscal year.
Investor Verification Checklist
- Verify the specific revenue and operating income targets for the 2017 fiscal year, as these are not disclosed in this filing.
- Confirm the "all or nothing" strategic goals defined for Landec, Apio, and Lifecore.
- Review the impact of the new equity grant on total executive compensation and potential dilution.
- Monitor future filings for the actual payout of bonuses based on 2017 performance.